vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and PROCORE TECHNOLOGIES, INC. (PCOR). Click either name above to swap in a different company.
PROCORE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($349.1M vs $263.6M, roughly 1.3× BALCHEM CORP). BALCHEM CORP runs the higher net margin — 14.9% vs -10.8%, a 25.7% gap on every dollar of revenue. On growth, PROCORE TECHNOLOGIES, INC. posted the faster year-over-year revenue change (15.6% vs 9.8%). Over the past eight quarters, PROCORE TECHNOLOGIES, INC.'s revenue compounded faster (13.8% CAGR vs 4.9%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Procore Technologies is an American construction management software as a service company founded in 2002, with headquarters in Carpinteria, California. Procore hosts a platform to connect those involved in the construction industry on a global platform. The software allows for the creation of simplified workflows and displays a consolidated view of construction products that includes the tracking of tasks, management of project workflows, and scheduling.
BCPC vs PCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $263.6M | $349.1M |
| Net Profit | $39.2M | $-37.6M |
| Gross Margin | 35.6% | 80.1% |
| Operating Margin | 19.8% | -12.3% |
| Net Margin | 14.9% | -10.8% |
| Revenue YoY | 9.8% | 15.6% |
| Net Profit YoY | 16.8% | 39.6% |
| EPS (diluted) | $1.21 | $-0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $263.6M | $349.1M | ||
| Q3 25 | $267.6M | $338.9M | ||
| Q2 25 | $255.5M | $323.9M | ||
| Q1 25 | $250.5M | $310.6M | ||
| Q4 24 | $240.0M | $302.0M | ||
| Q3 24 | $239.9M | $295.9M | ||
| Q2 24 | $234.1M | $284.3M | ||
| Q1 24 | $239.7M | $269.4M |
| Q4 25 | $39.2M | $-37.6M | ||
| Q3 25 | $40.3M | $-9.1M | ||
| Q2 25 | $38.3M | $-21.1M | ||
| Q1 25 | $37.1M | $-33.0M | ||
| Q4 24 | $33.6M | $-62.3M | ||
| Q3 24 | $33.8M | $-26.4M | ||
| Q2 24 | $32.1M | $-6.3M | ||
| Q1 24 | $29.0M | $-11.0M |
| Q4 25 | 35.6% | 80.1% | ||
| Q3 25 | 35.7% | 79.7% | ||
| Q2 25 | 36.4% | 79.1% | ||
| Q1 25 | 35.2% | 79.1% | ||
| Q4 24 | 36.0% | 81.2% | ||
| Q3 24 | 35.6% | 81.4% | ||
| Q2 24 | 35.5% | 83.1% | ||
| Q1 24 | 34.0% | 83.0% |
| Q4 25 | 19.8% | -12.3% | ||
| Q3 25 | 20.4% | -4.4% | ||
| Q2 25 | 20.1% | -9.3% | ||
| Q1 25 | 20.4% | -11.7% | ||
| Q4 24 | 19.8% | -21.9% | ||
| Q3 24 | 20.0% | -12.3% | ||
| Q2 24 | 19.6% | -5.2% | ||
| Q1 24 | 17.4% | -7.0% |
| Q4 25 | 14.9% | -10.8% | ||
| Q3 25 | 15.1% | -2.7% | ||
| Q2 25 | 15.0% | -6.5% | ||
| Q1 25 | 14.8% | -10.6% | ||
| Q4 24 | 14.0% | -20.6% | ||
| Q3 24 | 14.1% | -8.9% | ||
| Q2 24 | 13.7% | -2.2% | ||
| Q1 24 | 12.1% | -4.1% |
| Q4 25 | $1.21 | $-0.25 | ||
| Q3 25 | $1.24 | $-0.06 | ||
| Q2 25 | $1.17 | $-0.14 | ||
| Q1 25 | $1.13 | $-0.22 | ||
| Q4 24 | $1.03 | $-0.42 | ||
| Q3 24 | $1.03 | $-0.18 | ||
| Q2 24 | $0.98 | $-0.04 | ||
| Q1 24 | $0.89 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | $768.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $1.3B |
| Total Assets | $1.7B | $2.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $768.5M | ||
| Q3 25 | $65.1M | $684.0M | ||
| Q2 25 | $65.4M | $620.9M | ||
| Q1 25 | $49.9M | $566.7M | ||
| Q4 24 | $49.5M | $775.4M | ||
| Q3 24 | $73.7M | $756.9M | ||
| Q2 24 | $63.7M | $735.4M | ||
| Q1 24 | $60.3M | $744.6M |
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.2B | $1.2B | ||
| Q4 24 | $1.1B | $1.3B | ||
| Q3 24 | $1.2B | $1.3B | ||
| Q2 24 | $1.1B | $1.3B | ||
| Q1 24 | $1.1B | $1.2B |
| Q4 25 | $1.7B | $2.2B | ||
| Q3 25 | $1.7B | $2.1B | ||
| Q2 25 | $1.7B | $2.0B | ||
| Q1 25 | $1.6B | $1.9B | ||
| Q4 24 | $1.6B | $2.1B | ||
| Q3 24 | $1.6B | $2.0B | ||
| Q2 24 | $1.6B | $2.0B | ||
| Q1 24 | $1.6B | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $67.3M | $114.9M |
| Free Cash FlowOCF − Capex | — | $109.2M |
| FCF MarginFCF / Revenue | — | 31.3% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $282.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $67.3M | $114.9M | ||
| Q3 25 | $65.6M | $88.5M | ||
| Q2 25 | $47.3M | $30.8M | ||
| Q1 25 | $36.5M | $66.0M | ||
| Q4 24 | $52.3M | $29.1M | ||
| Q3 24 | $51.3M | $39.3M | ||
| Q2 24 | $45.0M | $58.7M | ||
| Q1 24 | $33.4M | $69.1M |
| Q4 25 | — | $109.2M | ||
| Q3 25 | — | $83.1M | ||
| Q2 25 | — | $27.9M | ||
| Q1 25 | — | $62.0M | ||
| Q4 24 | — | $17.4M | ||
| Q3 24 | — | $35.7M | ||
| Q2 24 | — | $56.8M | ||
| Q1 24 | — | $67.1M |
| Q4 25 | — | 31.3% | ||
| Q3 25 | — | 24.5% | ||
| Q2 25 | — | 8.6% | ||
| Q1 25 | — | 20.0% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | — | 12.1% | ||
| Q2 24 | — | 20.0% | ||
| Q1 24 | — | 24.9% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | 1.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
